$511 Million is the total value of Opaleye Management Inc.'s 55 reported holdings in Q3 2020. The portfolio turnover from Q2 2020 to Q3 2020 was 100.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| MGTA | Exit | MAGENTA THERAPEUTICS INC | $0 | – | -51,225 | -100.0% | -0.08% | – |
| ASRT | Exit | ASSERTIO HOLDINGS INC | $0 | – | -880,000 | -100.0% | -0.15% | – |
| AUTL | Exit | AUTOLUS THERAPEUTICS PLCsponsored ads | $0 | – | -60,000 | -100.0% | -0.19% | – |
| FENC | Exit | FENNEC PHARMACEUTICALS INC | $0 | – | -171,000 | -100.0% | -0.29% | – |
| ARDX | Exit | ARDELYX INC | $0 | – | -471,600 | -100.0% | -0.66% | – |
| LQDA | Exit | LIQUIDIA TECHOLOGIES INC | $0 | – | -400,000 | -100.0% | -0.68% | – |
| KALA | Exit | KALA PHARMACEUTICALS INC | $0 | – | -361,000 | -100.0% | -0.77% | – |
| BTAI | Exit | BIOXCEL THERAPEUTICS INC | $0 | – | -94,000 | -100.0% | -1.01% | – |
| CPRX | Exit | CATALYST PHARMACEUTICALS INC | $0 | – | -1,155,000 | -100.0% | -1.08% | – |
| TCDA | Exit | TRICIDA INC | $0 | – | -238,300 | -100.0% | -1.32% | – |
| MTEM | Exit | MOLECULAR TEMPLATES INC | $0 | – | -495,000 | -100.0% | -1.38% | – |
| QURE | Exit | VAXCYTE | $0 | – | -270,400 | -100.0% | -1.73% | – |
| ODT | Exit | ODONATE THERAPEUTICS INC | $0 | – | -250,000 | -100.0% | -2.14% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2020-11-16
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| CODEXIS INC | 39 | Q3 2023 | 10.9% |
| CHIMERIX INC | 31 | Q3 2022 | 16.4% |
| XOMA CORP DEL | 27 | Q3 2023 | 3.6% |
| FIBROGEN INC | 26 | Q1 2021 | 6.8% |
| BIOLINERX LTD (Does not reflect a reverse stock split effectuated after June 30, 2019) | 26 | Q1 2020 | 2.4% |
| OCULAR THERAPEUTIX INC | 24 | Q3 2023 | 17.6% |
| AXOGEN INC | 20 | Q4 2019 | 18.7% |
| ETON PHARMACEUTICALS INC | 20 | Q3 2023 | 5.6% |
| AMARIN CORP PLC | 20 | Q4 2020 | 6.6% |
| IMPRIMIS PHARMACEUTICALS INC | 19 | Q1 2020 | 5.9% |
View Opaleye Management Inc.'s complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| CHIMERIX INCSold out | February 13, 2023 | 0 | 0.0% |
| Larimar Therapeutics, Inc. | January 23, 2023 | 1,560,000 | 3.6% |
| TELA Bio, Inc. | June 10, 2022 | 1,557,500 | 10.7% |
| Gemini Therapeutics, Inc. /DESold out | February 01, 2022 | 0 | 0.0% |
| Adamas Pharmaceuticals IncSold out | January 26, 2022 | 0 | 0.0% |
| AVENUE THERAPEUTICS, INC. | February 12, 2021 | 9 | 11.0% |
| Cardiff Oncology, Inc. | February 12, 2021 | 9 | 11.0% |
| EDAP TMS SA | February 12, 2021 | 9 | 11.0% |
| Fortress Biotech, Inc. | February 12, 2021 | 9 | 11.0% |
| Gemini Therapeutics, Inc. /DE | February 12, 2021 | 9 | 11.0% |
View Opaleye Management Inc.'s complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2024-04-25 |
| 4 | 2024-04-24 |
| 4 | 2024-04-19 |
| SC 13G/A | 2024-04-09 |
| SC 13G | 2024-04-08 |
| 4 | 2024-03-28 |
| 4 | 2024-03-22 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
View Opaleye Management Inc.'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.